UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, UroGen Pharma currently has a consensus rating of “Buy” and an average target price of $43.70.

UroGen Pharma Trading Up 1.3 %

NASDAQ URGN opened at $10.37 on Wednesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a 50 day simple moving average of $10.92 and a 200-day simple moving average of $12.41. UroGen Pharma has a one year low of $9.78 and a one year high of $20.70.

Insider Activity

In related news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $59,000. China Universal Asset Management Co. Ltd. boosted its stake in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma during the fourth quarter worth about $126,000. Finally, Intech Investment Management LLC purchased a new stake in shares of UroGen Pharma in the 3rd quarter valued at about $155,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.